Skip to main content

Immune System

1
Pipeline Programs
3
Companies
2
Clinical Trials
1 recruiting
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
1
0
0
0
0
0
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

2 companies ranked by most advanced pipeline stage

Oxion Biologics
Oxion BiologicsSweden - Stockholm
1 program
1
OX118 or placeboPhase 11 trial
Active Trials
NCT07020156Recruiting32Est. Oct 2025
Human BioSciences
Human BioSciencesWV - Martinsburg
1 program
High saturated fat challenge mealN/A1 trial
Active Trials
NCT05792137Completed32Est. Oct 2024

Trial Timeline

Clinical trial activity over time

2023
2024
2025
2026
Oxion BiologicsOX118 or placebo
Human BioSciencesHigh saturated fat challenge meal

Clinical Trials (2)

Total enrollment: 64 patients across 2 trials

A First-in-Human Phase I Trial of OX118 in Healthy Volunteers

Start: Apr 2025Est. completion: Oct 202532 patients
Phase 1Recruiting
NCT05792137Human BioSciencesHigh saturated fat challenge meal

Postprandial Monocyte Study

Start: Nov 2023Est. completion: Oct 202432 patients
N/ACompleted

Phase Legend

PreclinicalLab & animal studies
Phase 1Safety & dosing
Phase 2Efficacy testing
Phase 3Large-scale trials
On MarketApproved & available

Key Insights

1 actively recruiting trials targeting 64 patients
3 companies competing in this space

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.